[go: up one dir, main page]

BR112018068045A2 - método in vitro para identificar aneurismas da aorta torácica (taa) em um indivíduo - Google Patents

método in vitro para identificar aneurismas da aorta torácica (taa) em um indivíduo

Info

Publication number
BR112018068045A2
BR112018068045A2 BR112018068045A BR112018068045A BR112018068045A2 BR 112018068045 A2 BR112018068045 A2 BR 112018068045A2 BR 112018068045 A BR112018068045 A BR 112018068045A BR 112018068045 A BR112018068045 A BR 112018068045A BR 112018068045 A2 BR112018068045 A2 BR 112018068045A2
Authority
BR
Brazil
Prior art keywords
taa
thoracic aortic
vitro method
expression
identify
Prior art date
Application number
BR112018068045A
Other languages
English (en)
Inventor
Oller Pedrosa Jorge
Miguel Redondo Moya Juan
Ramón Campanero Garcia Miguel
Mendez-Barbero Nerea
Original Assignee
Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P
Consejo Superior Investigacion
Univ Madrid Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P, Consejo Superior Investigacion, Univ Madrid Autonoma filed Critical Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P
Publication of BR112018068045A2 publication Critical patent/BR112018068045A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se a um método in vitro para rastrear indivíduos com risco de desenvolver aneurisma da aorta torácica (taa) ou uma doença que cause taa compreendendo: (a) medir o padrão ou nível de expressão de pelo menos disintegrina a e metaloproteinase com motivos trombospondina 1 (?a disintegrin and metalloproteinase with thrombospondin motifs 1?) (adamts1) obtida de uma amostra biológica isolada dos indivíduos a serem rastreados; e (b) comparar o referido padrão ou nível de expressão de pelo menos adamts1 dos indivíduos a serem rastreados com um padrão ou nível de expressão já estabelecido, onde a expressão reduzida de pelo menos adamts1 é indicativa de um aneurisma da aorta torácica (taa).
BR112018068045A 2016-03-07 2016-12-30 método in vitro para identificar aneurismas da aorta torácica (taa) em um indivíduo BR112018068045A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382103 2016-03-07
PCT/EP2016/082925 WO2017153023A1 (en) 2016-03-07 2016-12-30 In vitro method for identifying thoracic aortic aneurysms (taa) in a subject

Publications (1)

Publication Number Publication Date
BR112018068045A2 true BR112018068045A2 (pt) 2019-01-08

Family

ID=55524277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068045A BR112018068045A2 (pt) 2016-03-07 2016-12-30 método in vitro para identificar aneurismas da aorta torácica (taa) em um indivíduo

Country Status (8)

Country Link
US (2) US10907135B2 (pt)
EP (1) EP3427061B1 (pt)
JP (1) JP7057976B2 (pt)
AU (1) AU2016396401B2 (pt)
BR (1) BR112018068045A2 (pt)
CA (1) CA3017042C (pt)
ES (1) ES2965961T3 (pt)
WO (1) WO2017153023A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555790B1 (es) 2014-06-05 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de un array de micropartículas planares con multiplexado molecular superficial, array obtenido y su uso
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017093353A1 (en) 2015-12-01 2017-06-08 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Method for diagnosing cardiomyopathies
EA202091308A1 (ru) 2017-11-24 2020-09-11 Консехо Супериор Де Инвестигасионес Сьентификас (Ксис) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
EP3740592A4 (en) * 2018-02-19 2021-10-06 The General Hospital Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE
US12313635B2 (en) 2018-07-27 2025-05-27 The Regents Of The University Of California Biomarker for thoracic aortic aneurysm
CN115244400A (zh) * 2020-01-10 2022-10-25 德国巴伐利亚自由州慕尼黑心脏专科中心 - 慕尼黑工业大学诊所 通过检测血液样品中的特定生物标志物诊断主动脉夹层
US20210318336A1 (en) * 2020-04-09 2021-10-14 The Trustees Of The University Of Pennsylvania Methods for treating aortic aneurysm disease
WO2022219196A1 (en) * 2021-04-16 2022-10-20 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Method for the diagnosis, prognosis and/or treatment of thoracic aortic aneurysm

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
US20150203916A1 (en) * 2012-06-27 2015-07-23 Music Foundation For Research Development Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
ES2555790B1 (es) 2014-06-05 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Método de obtención de un array de micropartículas planares con multiplexado molecular superficial, array obtenido y su uso
ES2612340B1 (es) 2015-10-27 2018-03-09 Consejo Superior De Investigaciones Científicas (Csic) Sensor, aparato y procedimiento para la determinación de la concentración de solutos en disoluciones
WO2017093353A1 (en) 2015-12-01 2017-06-08 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) Method for diagnosing cardiomyopathies
KR20190003689A (ko) 2016-04-29 2019-01-09 유니버시다드 오토노마 데 마드리드 암 또는 면역계 질환을 가지는 환자에 대한 면역 치료 증강제 또는 보조제로서 사용하기 위한 생리활성 화합물을 운반하는 지질 시스템을 가지는 제제
EP3458584B1 (en) 2016-05-18 2021-07-07 Consejo Superior De Investigaciones Científicas Fusion proteins comprising an aldolase enzyme joined to a maltose binding protein
US20200270310A1 (en) 2017-09-15 2020-08-27 Fundacóin Para La Investigación Biomédica Del Hospital Universitario La Paz (F1Bhulp) Mafg as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells
WO2019086633A1 (en) 2017-11-02 2019-05-09 Consejo Superior De Investigaciones Científicas (Csic) Use of statins in overcoming resistance to beta-lactam antibiotics in bacterial species synthetizing isoprenoids using the mevalonate synthetic pathway
EA202091308A1 (ru) 2017-11-24 2020-09-11 Консехо Супериор Де Инвестигасионес Сьентификас (Ксис) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
EP3801555A1 (en) 2018-06-06 2021-04-14 Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) Enhanced trained immunity in myeloid cells by ship-1 inhibition
JP7260341B2 (ja) 2019-03-06 2023-04-18 スタンレー電気株式会社 車両用灯具の制御装置、車両用灯具の制御方法、車両用灯具システム

Also Published As

Publication number Publication date
EP3427061C0 (en) 2023-12-06
US20210363501A1 (en) 2021-11-25
JP2019510081A (ja) 2019-04-11
EP3427061B1 (en) 2023-12-06
ES2965961T3 (es) 2024-04-17
CA3017042C (en) 2024-02-20
AU2016396401A1 (en) 2018-10-25
US10907135B2 (en) 2021-02-02
AU2016396401B2 (en) 2023-07-13
WO2017153023A1 (en) 2017-09-14
JP7057976B2 (ja) 2022-04-21
US12163161B2 (en) 2024-12-10
EP3427061A1 (en) 2019-01-16
US20190112582A1 (en) 2019-04-18
CA3017042A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
BR112018068045A2 (pt) método in vitro para identificar aneurismas da aorta torácica (taa) em um indivíduo
BR112017005730A2 (pt) predição de evento de risco cardiovascular e usos da mesma
MX2021009682A (es) Biomarcadores de cinasa 2 dependientes de ciclinas y sus usos.
BR112018074071A2 (pt) método e sistema para a determinação in ovo não destrutiva de sexo de ave
BR112017010190A2 (pt) sistema para medição de características, método de medição
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
EP4282405A3 (en) Detection of cancer biomarkers using nanoparticles
BR112017000875A2 (pt) sistemas e métodos para classificação de padrões de dados de resposta locais do sensor, representativos da gravidade da patologia da rede de distribuição
BR112018000012A2 (pt) sistema e método de avaliação de função endotelial
EP3812746A4 (en) FLUORESCENT REAGENT PAPER FOR MEASURING MERCURY IONS AND MEASUREMENT PROCESS
EA201992026A1 (ru) Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5
BR112022011676A2 (pt) Kit para detectar um analito de interesse em uma pluralidade de amostras líquidas biológicas, método para detectá-lo e /ou quantificá-lo e cartucho para realizar tal método
BR112016017901A2 (pt) ensaio inovador para detectar periostina humana
Yin et al. High-content image-based single-cell phenotypic analysis for the testicular toxicity prediction induced by bisphenol A and its analogs bisphenol S, bisphenol AF, and tetrabromobisphenol A in a three-dimensional testicular cell co-culture model
Crowell et al. A simple model for the fate of the cytokinesis midbody remnant: Implications for remnant degradation by autophagy: Modeling remnant production and degradation enables re‐interpretation of published data and improves design of future experiments
MX384485B (es) Deteccion temprana de preeclampsia.
Misuth et al. Estimation of PKCδ autophosphorylation in U87 MG glioma cells: Combination of experimental, conceptual and numerical approaches
Hong et al. Polarized mechanosensitive signaling domains protect arterial endothelial cells against inflammation
AR117708A1 (es) Procedimiento in vitro para la detección de disbiosis intestinal aviar
PL406989A1 (pl) Profil mikro RNA we krwi jako test wykrywania raka płuca
Hendricusdottir et al. F-dynamics: Automated quantification of dendrite filopodia dynamics in living neurons
BR112018075820A2 (pt) método para inferir a atividade de um fator de transcrição de uma rota de transdução de sinal em um indivíduo, método para avaliar a adequação de uma terapia para um indivíduo, sistema para uso na inferência da atividade de um fator de transcrição de uma rota de transdução de sinal em um indivíduo, sistema para uso na avaliação da adequação de uma terapia para um indivíduo e programa de computador
PE20191707A1 (es) Composicion para la medicion, prevencion o alivio del envejecimiento de la piel usando hapln1
Luzhin et al. Automated analysis of cell cycle phase‐specific DNA damage reveals phase‐specific differences in cell sensitivity to etoposide

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]